All treatments
Treatment
Gemcitabine 2 g Powder for Solution for Infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
This study is for people with a type of non-muscle-invasive bladder cancer that has come back after treatment. We're testing a new drug, erdafitinib, against standard treatments to see which is better at preventing the cancer from returning.
For: Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or FusionsFrance · Germany · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
For: Non-small Cell Lung CancerCzechia · Poland · Greece